The earnings estimate of the financial year 2021 for Alexion Pharmaceuticals (NASDAQ: ALXN) has been upgraded by SVB Leerink analysts who expect a $14.71/share earnings instead of the prior $13.39 estimate. They have also given a ‘outperform’ recommendation with the price objective of $200. Alexion is expected to have an EPS of $4.12 in Q4 FY 2021.
On Wednesday, the company started from $157.91 in the stock market with the market cap being $34.56B. The lowest in 1 year is $72.67 while the highest is $160.03. Their current, quick, and debt-to-equity quotient are 3.81, 3.26, and 0.22. Their 50-day rolling average stands at $122.72 while the 200-day is at $114.35.
According to the 3rd November report, the company had a quarterly EPS earnings of $3.24, surpassing the $2.60 consensus estimate by $0.64. Their net margin was 16.32% with the equity return at 23.16%. Their quarterly revenue was $1.59B that surpassed the $1.43B estimate.
Undertakings Of ALXN Stock
Royal Canada Bank raised the price objective of Alexion Pharmaceuticals stock to $175 from $139 and gave a rating of ‘outperform’. BMO Cap Markets increased it to $175 from $152 but demoted the rating to ‘market perform’ from ‘outperform’. Credit Suisse raised it to $194 from $147 but reduced the rating to ‘neutral’ from ‘outperform’. William Blair reassigned their rating of ‘hold’. Roth Capital raised it to $73 from $50. The company has a consensus ‘hold’ recommendation with a $150.35 price objective.
Tanisha Carino, CAO, sold off 1,530 ALXN shares at $122.26 worth $187,057.80. Insiders own 4.03% ALXN stock.
RNC Cap Management increased its stake in ALXN stock by 2% in Q3, owning $2,498,000 worth of shares. Brinker Cap Investments purchased a new stake in Q3 priced at $1,424,000 while Bay Advisors purchased a new position valued at $440,000. Aurora Counsel purchased a new stake in Q3 at $656,000 and Jeppson management acquired a new stake at $35,000. 84.22% of the stock is owned by hedge funds and institutional investors.
